Longterm Safety Study of BEMA Buprenorphine in Subjects With Chronic Pain

Pain Clinical Trial

Official title:

A 52-Week, Open Label, Longterm Treatment Evaluation of the Safety and Efficacy of BEMA® Buprenorphine in Subjects With Moderate to Severe Chronic Pain

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01298765
• Other study ID #: BUP-305
• Status: Completed
• Phase: Phase 3
• Start date: March 2011
• Est. completion date: August 2012

Study information

• Verified date: March 2018
• Source: BioDelivery Sciences International
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether BEMA Buprenorphine is safe in the treatment of chronic pain.

Description:

This is an open label study of up to approximately 52 weeks duration to assess the safety and effectiveness of BEMA Buprenorphine in the management of moderate to severe chronic pain.

BEMA Buprenorphine is an oral transmucosal form of the opioid analgesic, buprenorphine hydrochloride, intended for application to the buccal mucosa. Buprenorphine is a synthetic opioid that is classified as a partial μ-receptor agonist and a Schedule III controlled substance in the United States.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 302
• Est. completion date: August 2012
• Est. primary completion date: August 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or non-pregnant and non-nursing female aged 18 or older

• History of moderate to severe chronic pain:

1. Subjects completing study BUP-301 (low back pain) or

2. Osteoarthritis or neuropathic pain, or subjects not completing study BUP-301 (low back pain), pain for =3 months with a pain intensity =5 [11 point NRS] reported at the titration period Day 0/1 visit following a washout period (opioids, NSAIDs, and muscle relaxants) of approximately 12 to 24 hours AND currently taking =60 mg oral morphine equivalent/day (including opioid-naïve) for 1 week or longer

• Stable health, as determined by the Investigator, on the basis of medical history, physical examination, and laboratory results so as to comply with all study procedures

• Female subjects of childbearing potential must be using a recognized effective method of birth control

• Written informed consent obtained prior to any procedure being performed

Exclusion Criteria:

• Cancer related pain

• Reflex sympathetic dystrophy or causalgia (complex regional pain syndrome), acute spinal cord compression, cauda equina compression, acute nerve root compression, meningitis, or discitis

• Surgical procedure for pain within 2 months, or nerve/plexus block within 4 weeks, prior to titration period Day 0/1 visit

• History of severe emesis with opioids

• Clinically significant sleep apnea in the judgment of the investigator

Related Conditions & MeSH terms

• Back Pain
• Chronic Pain
• Low Back Pain
• Neuralgia
• Neuropathic Pain
• Osteoarthritis
• Pain

Intervention

Drug:
• BEMA Buprenorphine
buccal soluble film; applied to the buccal mucosa twice daily

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
BioDelivery Sciences International

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in NRS Pain Intensity	The NRS Pain intensity score is a segmented version of a visual analog scale used to measure pain. The scale is from 0 (no pain) to 10. Scores between greater than 0 and 3 are considered mild pain, scores from greater than 3 to 6 are moderate and greater than 6 to 10 are severe. The daily average is calculated and used to calculate the change from baseline at week 52.	Baseline up to approximately Week 52
Secondary	Patient Global Impression of Change in Pain Intensity	Patient Global Impression of Change in Pain Intensity at Week 28 as measured by a 7 point scale. Patients measure their improvement from 7='very much improved', 6='much improved', 5='minimally improved', 4='no change', 3='minimally worse', 2='much worse', 1='very much worse'.	Baseline to Week 28
Secondary	Treatment Satisfaction Questionnaire for Medication/Global Satisfaction	Treatment Satisfaction Questionnaire for Medication/Global Satisfaction at Week 28. Patients complete a 14 item questionaire that measures 4 scales based on side effects, effectiveness, convenience and global satisfaction. All items have either five or seven responses (except item 4), scored from one (least satisfied) to five or seven (most satisfied). The 7-item scales have a non-neutral midpoint, such that there are more positive response options than negative response options. Item scores are summed to give four domain scores, which are in turn transformed to a scale of 0-100. Item 4 was not included for scoring. If an item score is missing and half of the items in the domain are complete, domain scores may be imputed from the person-specific mean score of completed items	Baseline to Week 28
Secondary	Subjects Overall Satisfaction With Study Drug	Subjects Overall Satisfaction with Study Drug as measured on a 5 point scale, with 1 being not satisfied and 5 being very satisified.	Baseline to Week 52
Secondary	Investigator's Overall Satisfaction With Study Drug	Investigator's Overall Satisfaction with Study Drug measured on a 5-point scale, with 1 being not satisfied and 5 being very satisfied.	Baseline to Week 52